Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment

Andrea De Barber, Limor Kalfon, Ayalla Fedida, Vered Fleisher Sheffer, Shani Ben Haroush, Natalia Chasnyk, Efrat Shuster Biton, Hanna Mandel, Krystal Jeffries, Eric S. Shinwell, Tzipora C. Falik-Zaccai

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cerebrotendinous xanthomatosis (CTX) is a progressive metabolic leukodystrophy. Early identification and treatment from birth onward effectively provides a functional cure, but diagnosis is often delayed. We conducted a pilot study using a two-tier test for CTX to screen archived newborn dried bloodspots (DBSs) or samples collected prospectively from a high-risk Israeli newborn population. All DBS samples were analyzed with flow injection analysis (FIA)-MS/MS, and 5% of samples were analyzed with LC-MS/MS. Consecutively collected samples were analyzed to identify CTX-causing founder genetic variants common among Druze and Moroccan Jewish populations. First-tier analysis with FIA-MS/MS provided 100% sensitivity to detect CTX-positive newborn DBSs, with a low false-positive rate (0.1-0.5%). LC-MS/MS, as a second-tier test, provided 100% sensitivity to detect CTX-positive newborn DBSs with a false-positive rate of 0% (100% specificity). In addition, 5β-cholestane-3α,7α,12α,25-tetrol-3-O-β-D-glucuronide was identified as the predominant bile-alcohol disease marker present in CTX-positive newborn DBSs. In newborns identifying as Druze, a 1:30 carriership frequency was determined for the c.355delC CYP27A1 gene variant, providing an estimated disease prevalence of 1:3,600 in this population. These data support the feasibility of two-tier DBS screening for CTX in newborns and set the stage for large-scale prospective pilot studies.

Original languageEnglish (US)
Pages (from-to)2214-2222
Number of pages9
JournalJournal of Lipid Research
Volume59
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Cerebrotendinous Xanthomatosis
Cholestanols
Screening
Glucuronides
Flow Injection Analysis
Genes
Population
Parturition
Prospective Studies

Keywords

  • bile acids and salts
  • diagnostic tools
  • inborn errors of metabolism
  • mass spectrometry
  • storage diseases

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

De Barber, A., Kalfon, L., Fedida, A., Fleisher Sheffer, V., Ben Haroush, S., Chasnyk, N., ... Falik-Zaccai, T. C. (2018). Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment. Journal of Lipid Research, 59(11), 2214-2222. https://doi.org/10.1194/jlr.M087999

Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment. / De Barber, Andrea; Kalfon, Limor; Fedida, Ayalla; Fleisher Sheffer, Vered; Ben Haroush, Shani; Chasnyk, Natalia; Shuster Biton, Efrat; Mandel, Hanna; Jeffries, Krystal; Shinwell, Eric S.; Falik-Zaccai, Tzipora C.

In: Journal of Lipid Research, Vol. 59, No. 11, 01.11.2018, p. 2214-2222.

Research output: Contribution to journalArticle

De Barber, A, Kalfon, L, Fedida, A, Fleisher Sheffer, V, Ben Haroush, S, Chasnyk, N, Shuster Biton, E, Mandel, H, Jeffries, K, Shinwell, ES & Falik-Zaccai, TC 2018, 'Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment', Journal of Lipid Research, vol. 59, no. 11, pp. 2214-2222. https://doi.org/10.1194/jlr.M087999
De Barber A, Kalfon L, Fedida A, Fleisher Sheffer V, Ben Haroush S, Chasnyk N et al. Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment. Journal of Lipid Research. 2018 Nov 1;59(11):2214-2222. https://doi.org/10.1194/jlr.M087999
De Barber, Andrea ; Kalfon, Limor ; Fedida, Ayalla ; Fleisher Sheffer, Vered ; Ben Haroush, Shani ; Chasnyk, Natalia ; Shuster Biton, Efrat ; Mandel, Hanna ; Jeffries, Krystal ; Shinwell, Eric S. ; Falik-Zaccai, Tzipora C. / Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment. In: Journal of Lipid Research. 2018 ; Vol. 59, No. 11. pp. 2214-2222.
@article{3d4551345a0642a1bd81697714d4a96c,
title = "Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment",
abstract = "Cerebrotendinous xanthomatosis (CTX) is a progressive metabolic leukodystrophy. Early identification and treatment from birth onward effectively provides a functional cure, but diagnosis is often delayed. We conducted a pilot study using a two-tier test for CTX to screen archived newborn dried bloodspots (DBSs) or samples collected prospectively from a high-risk Israeli newborn population. All DBS samples were analyzed with flow injection analysis (FIA)-MS/MS, and 5{\%} of samples were analyzed with LC-MS/MS. Consecutively collected samples were analyzed to identify CTX-causing founder genetic variants common among Druze and Moroccan Jewish populations. First-tier analysis with FIA-MS/MS provided 100{\%} sensitivity to detect CTX-positive newborn DBSs, with a low false-positive rate (0.1-0.5{\%}). LC-MS/MS, as a second-tier test, provided 100{\%} sensitivity to detect CTX-positive newborn DBSs with a false-positive rate of 0{\%} (100{\%} specificity). In addition, 5β-cholestane-3α,7α,12α,25-tetrol-3-O-β-D-glucuronide was identified as the predominant bile-alcohol disease marker present in CTX-positive newborn DBSs. In newborns identifying as Druze, a 1:30 carriership frequency was determined for the c.355delC CYP27A1 gene variant, providing an estimated disease prevalence of 1:3,600 in this population. These data support the feasibility of two-tier DBS screening for CTX in newborns and set the stage for large-scale prospective pilot studies.",
keywords = "bile acids and salts, diagnostic tools, inborn errors of metabolism, mass spectrometry, storage diseases",
author = "{De Barber}, Andrea and Limor Kalfon and Ayalla Fedida and {Fleisher Sheffer}, Vered and {Ben Haroush}, Shani and Natalia Chasnyk and {Shuster Biton}, Efrat and Hanna Mandel and Krystal Jeffries and Shinwell, {Eric S.} and Falik-Zaccai, {Tzipora C.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1194/jlr.M087999",
language = "English (US)",
volume = "59",
pages = "2214--2222",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "11",

}

TY - JOUR

T1 - Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment

AU - De Barber, Andrea

AU - Kalfon, Limor

AU - Fedida, Ayalla

AU - Fleisher Sheffer, Vered

AU - Ben Haroush, Shani

AU - Chasnyk, Natalia

AU - Shuster Biton, Efrat

AU - Mandel, Hanna

AU - Jeffries, Krystal

AU - Shinwell, Eric S.

AU - Falik-Zaccai, Tzipora C.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Cerebrotendinous xanthomatosis (CTX) is a progressive metabolic leukodystrophy. Early identification and treatment from birth onward effectively provides a functional cure, but diagnosis is often delayed. We conducted a pilot study using a two-tier test for CTX to screen archived newborn dried bloodspots (DBSs) or samples collected prospectively from a high-risk Israeli newborn population. All DBS samples were analyzed with flow injection analysis (FIA)-MS/MS, and 5% of samples were analyzed with LC-MS/MS. Consecutively collected samples were analyzed to identify CTX-causing founder genetic variants common among Druze and Moroccan Jewish populations. First-tier analysis with FIA-MS/MS provided 100% sensitivity to detect CTX-positive newborn DBSs, with a low false-positive rate (0.1-0.5%). LC-MS/MS, as a second-tier test, provided 100% sensitivity to detect CTX-positive newborn DBSs with a false-positive rate of 0% (100% specificity). In addition, 5β-cholestane-3α,7α,12α,25-tetrol-3-O-β-D-glucuronide was identified as the predominant bile-alcohol disease marker present in CTX-positive newborn DBSs. In newborns identifying as Druze, a 1:30 carriership frequency was determined for the c.355delC CYP27A1 gene variant, providing an estimated disease prevalence of 1:3,600 in this population. These data support the feasibility of two-tier DBS screening for CTX in newborns and set the stage for large-scale prospective pilot studies.

AB - Cerebrotendinous xanthomatosis (CTX) is a progressive metabolic leukodystrophy. Early identification and treatment from birth onward effectively provides a functional cure, but diagnosis is often delayed. We conducted a pilot study using a two-tier test for CTX to screen archived newborn dried bloodspots (DBSs) or samples collected prospectively from a high-risk Israeli newborn population. All DBS samples were analyzed with flow injection analysis (FIA)-MS/MS, and 5% of samples were analyzed with LC-MS/MS. Consecutively collected samples were analyzed to identify CTX-causing founder genetic variants common among Druze and Moroccan Jewish populations. First-tier analysis with FIA-MS/MS provided 100% sensitivity to detect CTX-positive newborn DBSs, with a low false-positive rate (0.1-0.5%). LC-MS/MS, as a second-tier test, provided 100% sensitivity to detect CTX-positive newborn DBSs with a false-positive rate of 0% (100% specificity). In addition, 5β-cholestane-3α,7α,12α,25-tetrol-3-O-β-D-glucuronide was identified as the predominant bile-alcohol disease marker present in CTX-positive newborn DBSs. In newborns identifying as Druze, a 1:30 carriership frequency was determined for the c.355delC CYP27A1 gene variant, providing an estimated disease prevalence of 1:3,600 in this population. These data support the feasibility of two-tier DBS screening for CTX in newborns and set the stage for large-scale prospective pilot studies.

KW - bile acids and salts

KW - diagnostic tools

KW - inborn errors of metabolism

KW - mass spectrometry

KW - storage diseases

UR - http://www.scopus.com/inward/record.url?scp=85055907610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055907610&partnerID=8YFLogxK

U2 - 10.1194/jlr.M087999

DO - 10.1194/jlr.M087999

M3 - Article

VL - 59

SP - 2214

EP - 2222

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 11

ER -